
<body>
  <app-root _nghost-c0="" ng-version="7.2.10"><main _ngcontent-c0="" class="main"><app-header _ngcontent-c0="" _nghost-c1=""><img _ngcontent-c1="" class="header-placeholder" src="/assets/images/header-img.png"><header _ngcontent-c1="" class="header"><section _ngcontent-c1="" class="header-wrapper"><div _ngcontent-c1="" class="menu-top"><a _ngcontent-c1="" class="navbar-logo" routerlink="/" href="/"><img _ngcontent-c1="" alt="ICH" src="/assets/images/ich-logo.png?v=2"></a><div _ngcontent-c1="" class="menu-right"><app-user-menu _ngcontent-c1="" _nghost-c5=""><section _ngcontent-c5="" class="user-menu"><ul _ngcontent-c5="" class="menu"><!----><li _ngcontent-c5=""><a _ngcontent-c5=""> Contact </a></li><li _ngcontent-c5=""><a _ngcontent-c5=""> Register </a></li></ul></section></app-user-menu><app-quick-links _ngcontent-c1="" _nghost-c6=""><section _ngcontent-c6="" class="quick-links"><ul _ngcontent-c6=""><li _ngcontent-c6=""><a _ngcontent-c6="" routerlink="/page/quality-guidelines" href="/page/quality-guidelines"><img _ngcontent-c6="" src="/assets/images/q.png"></a></li><li _ngcontent-c6=""><a _ngcontent-c6="" routerlink="/page/safety-guidelines" href="/page/safety-guidelines"><img _ngcontent-c6="" src="/assets/images/s.png"></a></li><li _ngcontent-c6=""><a _ngcontent-c6="" routerlink="/page/efficacy-guidelines" href="/page/efficacy-guidelines"><img _ngcontent-c6="" src="/assets/images/e.png"></a></li><li _ngcontent-c6=""><a _ngcontent-c6="" routerlink="/page/multidisciplinary-guidelines" href="/page/multidisciplinary-guidelines"><img _ngcontent-c6="" src="/assets/images/m.png"></a></li></ul></section></app-quick-links></div></div><div _ngcontent-c1="" class="menu-bottom"><app-nav-menu _ngcontent-c1="" _nghost-c7=""><section _ngcontent-c7="" class="nav-menu"><button _ngcontent-c7="" class="menu-hamburger"></button><section _ngcontent-c7="" class="menu-main-links"><ul _ngcontent-c7="" class="menu"><li _ngcontent-c7="" class="home menu-item btn"><a _ngcontent-c7="" routerlink="/" href="/">Home</a></li><!----><li _ngcontent-c7="" togglemenu="" class="menu-item menu-0 btn nav-button"> About ICH <!----><ul _ngcontent-c7="" class="sub-menu"><!----><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">About ICH</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Mission</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">History</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Transparency</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Funding</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Work with ICH</a></li></ul></li><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">Organisation</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Organisational Chart</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Members &amp; Observers</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Value of Membership</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Application Process</a></li></ul></li><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">Key Documents</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Articles &amp; Procedures</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Work Plans &amp; Reports</a></li></ul></li></ul></li><li _ngcontent-c7="" togglemenu="" class="menu-item menu-1 btn nav-button active"> Work Products <!----><ul _ngcontent-c7="" class="sub-menu"><!----><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">ICH Harmonisation Activities</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Process of Harmonisation</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Public Consultations</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Guideline Implementation</a></li></ul></li><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">ICH Guidelines</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">All Guidelines</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Quality Guidelines</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Safety Guidelines</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Efficacy Guidelines</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Multidisciplinary Guidelines</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Index of Guidelines</a></li></ul></li><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">ICH Standards</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">MedDRA</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">CTD</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Electronic Standards (ESTRI)</a></li></ul></li><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">Other Work Products</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Reflection Papers &amp; Discussion Groups</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Consideration Documents</a></li></ul></li></ul></li><li _ngcontent-c7="" togglemenu="" class="menu-item menu-2 btn nav-button"> Meetings <!----><ul _ngcontent-c7="" class="sub-menu"><!----><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">Meetings</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">ICH Calendar</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Assembly</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Management Committee</a></li></ul></li><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">ICH Public Events</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">ICH Public Events</a></li></ul></li></ul></li><li _ngcontent-c7="" togglemenu="" class="menu-item menu-3 btn nav-button"> Training <!----><ul _ngcontent-c7="" class="sub-menu"><!----><li _ngcontent-c7="" class="sub-menu-item"><!----><a _ngcontent-c7="" class="first-submenu-item">Training</a><!----><ul _ngcontent-c7="" class="menu-column"><!----></ul></li></ul></li><li _ngcontent-c7="" togglemenu="" class="menu-item menu-4 btn nav-button"> Newsroom <!----><ul _ngcontent-c7="" class="sub-menu"><!----><li _ngcontent-c7="" class="sub-menu-item"><!----><!----><p _ngcontent-c7="" class="first-submenu-item">Newsroom</p><ul _ngcontent-c7="" class="menu-column"><!----><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">News</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Publications</a></li><li _ngcontent-c7=""><a _ngcontent-c7="" class="second-submenu-item">Press Releases</a></li></ul></li></ul></li></ul><section _ngcontent-c1="" class="wrapper input search"><input _ngcontent-c1="" id="search" placeholder="Search..." type="search" class="ng-untouched ng-pristine ng-valid"><label _ngcontent-c1="" for="search"><i _ngcontent-c1="" class="ion ion-ios-search"></i></label></section></section><ul _ngcontent-c7="" class="social-list"><li _ngcontent-c7="" class="social-list-item"><a _ngcontent-c7="" class="ion ion-logo-rss" target="_blank" href="https://admin.ich.org/rss/news"></a></li><li _ngcontent-c7="" class="social-list-item"><a _ngcontent-c7="" class="ion ion-logo-twitter twitter" href="http://twitter.com/home?status=https%3A%2F%2Fwww.ich.org%2Fhome.html" target="_blank"></a></li><li _ngcontent-c7="" class="social-list-item"><a _ngcontent-c7="" class="ion ion-logo-linkedin linkedin" href="http://www.linkedin.com/shareArticle?mini=true&amp;url=https%3A%2F%2Fwww.ich.org%2Fhome.html&amp;title=Home" target="_blank"></a></li><li _ngcontent-c7="" class="social-list-item"><span _ngcontent-c7="" class="icon ion-md-print"></span></li></ul></section></app-nav-menu></div></section></header></app-header><div _ngcontent-c0="" class="main-container"><app-breadcrumb _ngcontent-c0="" _nghost-c2=""><!----><section _ngcontent-c2="" class="breadcrumbs"><!----><span _ngcontent-c2=""> Home <!----><span _ngcontent-c2="" class="divider"> \ </span></span><span _ngcontent-c2=""> ICH Guidelines <!----><span _ngcontent-c2="" class="divider"> \ </span></span><span _ngcontent-c2=""> Quality Guidelines <!----></span></section></app-breadcrumb><router-outlet _ngcontent-c0=""></router-outlet><app-base-page _nghost-c8=""><section _ngcontent-c8="" class="main-page"><!----><app-page _ngcontent-c8="" _nghost-c9="" class="ng-star-inserted"><!----><article _ngcontent-c9="" class="page ng-star-inserted" editwidget="" style="position: relative;"><h1 _ngcontent-c9="" class="page-title">Quality Guidelines</h1><!----><div _ngcontent-c9="" class="top-details"><!----><!----></div><!----><section _ngcontent-c9="" class="ng-star-inserted"><!----><!----><!----><!----><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><app-paragraph-title _ngcontent-c12="" _nghost-c15="" class="ng-star-inserted"><h2 _ngcontent-c15="" class="widget-title"></h2><p _ngcontent-c15="" class="paragraph-content"><p class="text-align-justify">Harmonisation achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management.</p>
</p></app-paragraph-title><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-0 ng-star-inserted"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-0"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q1A - Q1F Stability</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-1 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-1"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q1A(R2)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Stability Testing of New Drug Substances and Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This Guideline has been revised a second time and has reached <em>Step 4</em> of the ICH process in February 2003. This Guideline provides recommendations on stability testing protocols including temperature, humidity and trial duration for Climatic Zone I and II. Furthermore, the revised document takes into account the requirements for stability testing in Climatic Zones III and IV in order to minimise the different storage conditions for submission of a global dossier.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">6 February 2003</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 7 November 2019; Reference: RDC nÂº 318/2019
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">COFEPRIS, Mexico</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2015; Reference: NOM-073-SSA1-2015
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 August 2003; Reference: CPMP/ICH/2736/99
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2003; Reference: Vol. 68, No. 225, p. 65717-18
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: Stability guidelines
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 25 September 2003; Reference: File #: 03-118437-914
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 14 June 2016; Reference: Regulation on Stability Test of Pharmaceuticals [Appendix 4] Stability Testing Standard of New Drugs MFDS, Republic of Korea Notification
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2003; Reference: PFSB/ELD Notification No. 0603001
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2015; Reference: Technical Guideline for the Study of Stability of Chemical Drugs (APIs and Preparations, published by NMPA, China, 2015)
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 3 May 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 2003; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 1 April 2005; Reference: Guideline on Stability Testing of Drug Substances and Products
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TITCK, Turkey</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2017;</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf"> Q1A(R2) Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-2 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-2"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q1B</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Stability Testing : Photostability Testing of New Drug Substances and Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in November 1996. This document is an annex to the main stability Guideline, and gives guidance on the basic testing protocol required to evaluate the light sensitivity and stability of new drugs and products.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">6 November 1996</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 7 November 2019; Reference: RDC nÂº 318/2019
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">COFEPRIS, Mexico</span> - <span _ngcontent-c32="">Implemented; Date: 5 September 2015; Reference: NOM-073-SSA1-2015
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 1996; Reference: CPMP/ICH/279/95
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 1997; Reference: Vol. 62, No. 95, p. 27115-27122
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: Stability guidelines
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 12 February 1999; Reference: Catalogue No. H42-2/77-1998E
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 14 June 2016; Reference: Regulation on Stability Test of Pharmaceuticals [Appendix 6] Photostability Testing of New Drugs MFDS, Republic of Korea Notification Guideline on photostability testing of Drugs [Guideline-0205-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 1997; Reference: PAB/PCD Notification No. 422
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2015; Reference: Technical Guideline for the Study of Stability of Chemical Drugs (APIs and Preparations, published by NMPA, China, 2015)
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 3 May 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 6 November 1996; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 July 1998; Reference: Guideline on Stability Testing of Drug Substances and Products
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf"> Q1B Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-3 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-3"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q1C</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Stability Testing for New Dosage Forms</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4 </em>in November 1996. It extends the main stability Guideline for new formulations of already approved medicines, and defines the circumstances under which reduced stability data can be accepted.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">6 November 1996</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 7 November 2019; Reference: RDC nÂº 318/2019
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">COFEPRIS, Mexico</span> - <span _ngcontent-c32="">Not applicable; Date: 1 September 2015; Reference: &nbsp;NOM-073-SSA1-2015
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 1996; Reference: CPMP/ICH/280/95
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 1997; Reference: Vol. 62, No. 90, p. 25634-5
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: Stability guidelines
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 18 January 1999; Reference: Catalogue No. H42-2/78-1998E
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 14 June 2016; Reference: Regulation on Stability Test of Pharmaceuticals [Appendix 5] Stability Testing of New Dosage Forms of New Drugs [ MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 1997; Reference: PAB/PCD Notification No. 425
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2015; Reference: Technical Guideline for the Study of Stability of Chemical Drugs (APIs and Preparations, published by NMPA, China, 2015)
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 5 March 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 6 November 1996; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 July 1998; Reference: Guideline on Stability Testing of Drug Substances and Products
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q1C%20Guideline.pdf"> Q1C Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-4 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-4"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q1D</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in February 2002. This document is intended to address recommendations on the application of bracketing and matrixing to stability studies conducted in accordance with principles outlined in the main stability Guideline.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">7 February 2002</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 7 November 2019; Reference: RDC nÂº 318/2019
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">COFEPRIS, Mexico</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2015; Reference: &nbsp;NOM-073-SSA1-2015
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 2002; Reference: CPMP/ICH/4104/00
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2003; Reference: Vol. 68, No. 11, p. 2339-2340
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: Stability guidelines
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 25 September 2003; Reference: File #: 03-118449-498
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 14 June 2016; Reference: Regulation on Stability Test of Pharmaceuticals [Appendix 7] Bracketing and Matrixing Designs for New Drugs [ MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2002; Reference: PFSB/ELD Notification No. 0731004
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2015; Reference: Technical Guideline for the Study of Stability of Chemical Drugs (APIs and Preparations, published by NMPA, China, 2015)
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 5 March 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 7 February 2002; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 1 April 2005; Reference: Guideline on Stability Testing of Drug Substances and Products
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q1D%20Guideline.pdf"> Q1D Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-5 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-5"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q1E</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Evaluation of Stability Data</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in February 2003. This document extends the main stability Guideline by explaining possible situations where extrapolation of retest periods or shelf-lives beyond the real-time data may be appropriate. Furthermore, it provides examples of statistical approaches to stability data analysis.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">6 February 2003</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 7 November 2019; Reference: RDC nÂº 318/2019
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">COFEPRIS, Mexico</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2015; Reference: NOM-073-SSA1-2015
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 March 2003; Reference: CPMP/ICH/420/02
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2004; Reference: Vol. 69, No. 110, p. 32010-11
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: Stability guidelines
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 25 September 2003; Reference: File #: 03-118451-122
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 14 June 2016; Reference: Regulation on Stability Test of Pharmaceuticals [Appendix 8] Evaluation of Stability Data [ MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2003; Reference: PFSB/ELD Notification No. 0603004
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2015; Reference: Technical Guideline for the Study of Stability of Chemical Drugs (APIs and Preparations, published by NMPA, China, 2015)
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 5 March 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 6 February 2003; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 1 April 2005; Reference: Guideline on Stability Testing of Drug Substances and Products
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q1E%20Guideline.pdf"> Q1E Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q1E%20Presentation.pdf"> Q1E Presentation </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-6 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-6"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q1F</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Stability Data Package for Registration Applications in Climatic Zones III and IV</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Steering Committee endorsed the withdrawal of the Q1F Guideline at Yokohama meeting in June 2006, and decided to leave definition of storage conditions in Climatic Zones III and IV to the respective regions and WHO.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Withdrawn</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><!----></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf"> Q1F Stability Guideline WHO 2018 </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q1F_Explanatory_Note.pdf"> Q1F Explanatory Note </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-7 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-7"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q1/Q5C informal WG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Targeted Revisions of the ICH Stability Guideline Series </span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This topic was endorsed by the ICH Assembly in June 2021, and an informal Working Group has been established to develop a Concept Paper and Business Plan.</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Ms. Megan McMahon (PhRMA)</p></div></div><!----></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-8 ng-star-inserted"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-8"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q2 Analytical Validation</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-9 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-9"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q2(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Validation of Analytical Procedures: Text and Methodology</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline on Text (previously coded Q2A) was finalised under <em>Step 4</em> in October 1994. This identifies the validation parameters needed for a variety of analytical methods. It also discusses the characteristics that must be considered during the validation of the analytical procedures which are included as part of registration applications.</p>

<p>&nbsp;</p>

<p>The ICH Harmonised Guideline on Methodology (previously coded Q2B) was finalised under <em>Step 4</em> in November 1996. It extends the Guideline Q2A to include the actual experimental data required, along with the statistical interpretation, for the validation of analytical procedures. The Guideline on Methodology has been incorporated into the Guideline on Text in November 2005 and then renamed Q2(R1), without any changes in the contents of the two Guidelines.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">1 November 2005</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2017; Reference: RDC 166/2017 and RDC 413/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 1996; Reference: CPMP/ICH/381/95
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 1997; Reference: Vol. 62, No. 96, p. 27463-7
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: Analytical Validation Guidelines
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 June 2015; Reference: File #: 15-106599-601
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2015; Reference: Regulation on Safety of Pharmaceuticals, etc. [Prime Minister Decree] Korean Pharmacopoeia : Validation of Analytical Procedures for Pharmaceuticals [MFDS, Republic of Korea Notification] Validation of Analytical Procedures for Pharmaceuticals [Guideline 0213-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 October 1997; Reference: PMSB/ELD Notification No. 338
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 July 2020; Reference: NMPA, China Announcement No. 7 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 22 September 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 6 November 1996; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 15 June 2000; Reference: Guidance for Analytical Validation
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf"> Q2(R1) Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-10 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-10"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q2(R2)/Q14 EWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Analytical Procedure Development and Revision of Q2 (R1) Analytical Validation</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This topic was endorsed by the Assembly in June 2018.</p>

<p>The Q2(R2)/Q14 EWG will develop a new ICH Quality Guideline, ICH Q14, on Analytical Procedure Development, and revise the ICH Q2(R1) Guideline on Validation of Analytical Procedures, with a view to potentially combine both documents into one, for simplification and clarity.</p>

<p><strong>Q2(R1) Revision </strong></p>

<p>The scope of the revision of ICH Q2(R1) will include validation principles that cover analytical use of spectroscopic or spectrometry data (e.g., NIR, Raman, NMR or MS) some of which often require multivariate statistical analyses. The guideline will continue to provide a general framework for the principles of analytical procedure validation applicable to products mostly in the scope of Q6A and Q6B. These proposed guidelines (Q2(R2) and Q14) are intended to complement ICH Q8 to Q12 Guidelines, as well as on-going ICH Q13 for Continuous Manufacturing.</p>

<p><strong>Q14 Analytical Procedure Development Guideline </strong></p>

<p>The new guideline is proposed to harmonise the scientific approaches of Analytical Procedure Development, and to provide the principles relating to the description of Analytical Procedure Development process. This new guideline is intended to improve regulatory communication between industry and regulators and facilitate more efficient, sound scientific and risk-based approval as well as post-approval change management of analytical procedures.</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Dr. Yukio Hiyama (MHLW/PMDA, Japan)</p></div><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Regulatory Chair</b>: Dr. David Keire (FDA, United States)</p></div></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 2b</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">24 March 2022</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 3</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Public consultation dates:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Deadline for comments by 31 August 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Deadline for comments by 28 September 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Deadline for comments by 13 September 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Deadline for comments by 25 August 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHRA, UK</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Deadline for comments by 15 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2R2-Q14_EWG_Concept_Paper.pdf"> Q2(R2)/Q14 Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2R2-Q14_EWG_Business_Plan.pdf"> Q2(R2)/Q14 Business Plan </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2%28R2%29Q14_EWG_WorkPlan_2022_0210.pdf"> Q2(R2)/Q14 Work Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations/Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2_Q14%20ICH_Step_2_Presentation_2022_0325.pdf"> Q2(R2)/Q14 Step 2 Presentation </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf"> Q2(R2) Draft Guideline </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q14_Document_Step2_Guideline_2022_0324.pdf"> Q14 Draft Guideline </a></div><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-11 ng-star-inserted"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-11"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q3A - Q3E Impurities</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-12 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-12"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q3A(R2)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Impurities in New Drug Substances</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>First recommended for adoption at <em>Step 4</em> of the ICH Process on 30 March 1995, the Guideline was revised under <em>Step 2</em> of the ICH Process on 7 October 1999 and finalised under <em>Step 4</em> on 7 February 2002 (Q3A(R1)).</p>

<p>&nbsp;</p>

<p>The Guideline addresses the chemistry and safety aspects of impurities, including the listing of impurities in specifications and defines the thresholds for reporting, identification and qualification. The revision of the Guideline has allowed clarifying some inconsistencies, to revise the decision tree, to harmonise with Q3B and to address some editorial issues.</p>

<p>&nbsp;</p>

<p>The Attachment 2 of this Guideline has been revised under <em>Step 4</em> without further public consultation on 25 October 2006 (Q3A(R2)).</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">25 October 2006</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 3 August 2020; Reference: RDC 359/2020 and RDC 361/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 October 2006; Reference: CPMP/ICH/2737/99
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2008; Reference: Published in the Federal Register
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: These guidelines are cross-referred in M4Q and applied in the routine evaluation. See regulatory guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 June 2015; Reference: File #: 15-106606-354
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 22 June 2018; Reference: Regulation on Pharmaceuticals Approval, Notification and Review [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2006; Reference: PFSB/ELD Notification No. 1204001
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 July 2020; Reference: NMPA, China Announcement No. 7 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 22 September 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 25 October 2006; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 26 October 2021; Reference: Guidance for "Impurities in New Drug Substances and New Drug Products".
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf"> Q3A(R2) Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-13 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-13"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q3B(R2)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Impurities in New Drug Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This Guideline has been first revised and finalised under <em>Step 4</em> in February 2003. It complements the Guideline on impurities in new drug substances and provides advice in regard to impurities in products containing new, chemically synthesized drug substances. The Guideline specifically deals with those impurities which might arise as degradation products of the drug substance, or arising from interactions between drug substance and excipients or components of primary packaging materials. The Guideline sets out a rationale for the reporting, identification and qualification of such impurities based on a scientific appraisal of likely and actual impurities observed, and of the safety implications, following the principles elaborated in the parent Guideline. Threshold values for reporting and control of impurities are proposed, based on the maximum daily dose of the drug substance administered in the product.</p>

<p>&nbsp;</p>

<p>The Attachment 2 of this Guideline has been revised under <em>Step 4</em> without further public consultation on 2 June 2006 (Q3B(R2)).</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">2 June 2006</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">In the process of implementation; Date: 31 December 2023; Reference: RDC 53/2015
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2006; Reference: CPMP/ICH/2738/99
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2003; Reference: Vol, 68, No. 220, p. 64628-9
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: These guidelines are cross-referred in M4Q and applied in the routine evaluation. See regulatory guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 15 June 2015; Reference: File #: 15-106634-508
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 30 July 2018; Reference: Impurities in New Drug Products[Guideline-0877-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2006; Reference: PFSB/ELD Notification No. 0703004
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 July 2020; Reference: NMPA, China Announcement No. 7 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 22 September 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 2 June 2006; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 26 November 2021; Reference: Guidance for "Impurities in New Drug Substances and New Drug Products".
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf"> Q3B(R2) Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3B%28R2%29%20Concept%20Paper.pdf"> Q3B(R2) Concept Paper </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-14 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-14"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q3C(R8)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Guideline for Residual Solvents</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p><span><span>The Q3C ICH Guideline was finalised under Step 4 in July 1997, providing recommendations on the use of less toxic solvents in the manufacture of drug substances and dosage forms, and setting pharmaceutical limits for residual solvents (organic volatile impurities) in drug products. A Maintenance process for the Q3C Guideline was setup to enable the revision and inclusion of new Permitted Daily Exposure (PDE) levels as new toxicological data for solvents become available.</span></span></p>

<p>&nbsp;</p>

<p><span><span>As part of the Maintenance Process, the Q3C(R8) Guideline incorporated the PDE levels for 2-methyltetrahydrofuran, cyclopentylmethylether and tert-butanol.</span></span></p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">22 April 2021</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Not yet implemented; Date: 1 November 2029;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">In the process of implementation; Date: 20 November 2021; Reference: EMA/CHMP/ICH/82260/2006
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 13 December 2021; Reference: 86 FR 70850, 70850-70852
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2021;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 4 June 2021; Reference: File #: 21-109767-280
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 15 July 2021; Reference: Korean Pharmacopoeia: Guideline of Residual Solvents Test (MFDS, Republic of Korea Notification)
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 13 August 2021; Reference: PSEHB/PED Notification No. 0813-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 February 2022; Reference: (NMPA, China Announcement No. 152; 2021)&nbsp;
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 22 September 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 22 April 2021; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 24 February 2022; Reference: Updated-Announcement for ICH Guidelines Recognition List
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3C%20Concept%20Paper_0.pdf"> Q3C Concept Paper </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline </span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422_1.pdf"> Q3C(R8) Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q3C-R8_Step4_Presentation_2021_0422.pdf"> Q3C(R8) Step 4 Presentation </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-zip ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q3C_Support_Documents_2020_0116_0.zip"> Q3C Support Documents </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-15 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-15"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q3C(R9) Maintenance EWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title"> Maintenance of the Guideline for Residual Solvents</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The Q3C ICH Guideline was finalised under Step 4 in July 1997, providing recommendations on the use of less toxic solvents in the manufacture of drug substances and dosage forms, and setting pharmaceutical limits for residual solvents (organic volatile impurities) in drug products.</p>

<p>&nbsp;</p>

<p><strong>Maintenance Process</strong></p>

<p>A Maintenance process for the Q3C Guideline was setup to enable the revision and inclusion of new Permitted Daily Exposure (PDE) levels as new toxicological data for solvents become available.&nbsp;</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Dr. Akihiko Hirose (MHLW/PMDA, Japan)</p></div></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 1</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><!----></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3C%20Concept%20Paper_0_0.pdf"> Concept Paper </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-zip ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q3C_Support_Documents_2020_0116_0_0.zip"> Support Documents </a></div><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-16 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-16"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q3D(R2)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Guideline for Elemental Impurities</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>ICH Q3D(R2) Guideline for Elemental Impurities is a quality guideline for the control of elemental impurities in new drug products (medicinal products), and it establishes Permitted Daily Exposures (PDEs) for 24 Elemental Impurities (EIs) for drug products administered by the oral, parenteral and inhalation routes of administration. In addition, guidance is provided in Q3D(R2) on how to develop an acceptable level for EIs for drug products administered by other routes of administration.</p>

<p>&nbsp;</p>

<p>The current Q3D(R2) Guideline reached <em>Step 4</em> in April 2022, and included a correction of PDEs for Gold, Silver and Nickel; Gold and Silver monographs; and an addition of limits for elemental impurities by the cutaneous and transcutaneous route. The Q3D(R2) Guideline replaces the previous Q3D(R1) Guideline, which reached <em>Step 4</em> of the ICH process in 2019,&nbsp;&nbsp;further to the initial Q3D Guideline which reached <em>Step 4</em> in 2014.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">26 April 2022</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><!----></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3D%28R2%29%20Concept%20Paper_1.pdf"> Q3D(R2) Maintenance Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3D%28R2%29_EWG_WorkPlan_2022_0204.pdf"> Q3D(R2) Maintenance Work Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q3D%28R2%29_Step4Presentation_2022_0527.pdf"> Q3D(R2) Step 4 Presentation </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3D-R2_Guideline_Step4_2022_0308.pdf"> Q3D(R2) Guideline  </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-17 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-17"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q3D(R3) Maintenance EWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Maintenance of the Guideline for Elemental Impurities</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Q3D Guideline was finalised under <em>Step 4</em> in November 2014. It is a quality guideline for the control of elemental impurities in new drug products (medicinal products), and it establishes Permitted Daily Exposures (PDEs) for Elemental Impurities (EIs) for drug products administered by the oral, parenteral and inhalation routes of administration. In addition, guidance is provided in ICH Q3D on how to develop an acceptable level for EIs for drug products administered by other routes of administration.</p>

<p>&nbsp;</p>

<p>The Q3D(R1) and Q3D(R2) Guidelines reached <em>Step 4</em> of the ICH process in March 2019 and April 2022, respectively.&nbsp;</p>

<p>&nbsp;</p>

<p><strong>Maintenance Process</strong><br>
A maintenance procedure for the Q3D Guideline was setup to enable incorporation of Permitted Daily Exposure (PDE) for new elemental impurities (EI)/routes of administration and revising the PDE for EI as new toxicological data for EI becomes available.</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Dr. Roland Froetschl (EC, Europe)</p></div></div><!----></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Files</span><!----><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-18 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-18"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q3D training</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Implementation of Guideline for Elemental Impurities</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The Q3D Implementation Working Group (IWG) was endorsed by the ICH Steering Committee in October 2014. Throughout the development of the Q3D Guideline, external audiences, constituents and interested parties have clearly communicated the complexity of the implementation approaches for this Guideline. The ICH Steering Committee considered that the development of a comprehensive training programme and supporting documentation sponsored by ICH was necessary to ensure the proper interpretation and effective utilisation by industry and regulators alike to enable a Harmonised and smooth implementation of Q3D on a global basis. The first training package (Modules 0-7) was endorsed by the ICH Assembly in December 2015. The final Modules 8-9 of the Q3D training package were endorsed by the ICH Assembly in June 2016.</p>
</p></div><!----><!----></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3D%20Training%20Concept%20Paper.pdf"> Q3D Training Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3D%20Training%20Business%20Plan.pdf"> Q3D Training Business Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-zip ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Training_package_Module_0_9%20%283%29.zip"> Q3D Training Package Module 0-9 </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-19 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-19"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q3E EWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Impurity: Assessment and Control of Extractables and Leachables for Pharmaceuticals and Biologics</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This topic was endorsed by the ICH Assembly in June 2019.</p>

<p>&nbsp;</p>

<p>Further to the MC's endorsement of the Q3E Concept Paper and Business Plan in July 2020, the Q3E EWG was established to work on the development of the Q3E Guideline&nbsp;on the assessment and control of extractables and leachables (E&amp;L), and is expected would assist both<br>
applicants and regulators by providing focus on critical aspects, and improving transparency&nbsp;in requirements for medicinal products including drug delivery device components.</p>

<p>&nbsp;</p>

<p>Further information can be found in the Q3E Concept Paper and Business Plan.</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Dr. Kim Li (PhRMA)</p></div><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Regulatory Chair</b>: Dr. Jason Rodriguez (FDA, United States)</p></div></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 1</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><!----></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q3E_ConceptPaper_2020_0710.pdf"> Q3E Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q3E_Business_Plan_2020_0710.pdf"> Q3E Business Plan </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q3E_EWG_WorkPlan_2021_1216.pdf"> Q3E Work Plan </a></div><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-20 ng-star-inserted"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-20"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q4A - Q4B Pharmacopoeias</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-21 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-21"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4A</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Pharmacopoeial Harmonisation</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The pharmacopoeial authorities, working together through the Pharmacopoeial Discussion Group (PDG), have been closely involved with the work of ICH since the outset and harmonisation between the major pharmacopoeias, which started before ICH, has proceeded in parallel.</p>
</p></div><!----><!----></section><!----></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-22 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-22"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under<em> Step 4</em> in November 2007. This document describes a process for the evaluation and recommendation by the Q4B Expert Working Group (EWG) of selected pharmacopoeial texts to facilitate their recognition by regulatory authorities for use as interchangeable in the ICH regions. Following favourable evaluations, ICH decided to issue topic-specific annexes with information about these texts and their implementation. Implementation of the Q4B annexes is intended to avoid redundant testing by industry. Given the nature of this topic, no Concept Paper was developed for Q4B.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">1 November 2007</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2007; Reference: CHMP/ICH/222007/2006
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 2008; Reference: Vol. 73, No. 35, p.&nbsp;9575-6
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 29 September 2010; Reference: File #: 10-120634-491
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 5 December 2014; Reference: Korean Pharmacopoeia [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 2009; Reference: PFSB/ELD Notification No. 0526001
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2007; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 10 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Guideline.pdf"> Q4B Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Presentation.pdf"> Q4B Presentation </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April_.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-23 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-23"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 1(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Residue on Ignition/Sulphated Ash General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in November 2007. This annex is the result of the Q4B process for Residue on Ignition/Sulphated Ash General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/222063/2006
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 73, No. 35, p.&nbsp;9576-7
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 13 October 2010; Reference: File #: 10-121155-764
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 28 December 2007; Reference: Korean Pharmacopoeia : Loss on Ignition Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 2009; Reference: PFSB/ELD Notification No. 052 6002
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 10 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%201%28R1%29%20Guideline.pdf"> Q4B Annex 1(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__0.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-24 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-24"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 2(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Test for Extractable Volume of Parenteral Preparations General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in June 2008. This annex is the result of the Q4B process for the Test for Extractable Volume of Parenteral Preparations General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/559409/2007
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 74, No. 6, p. 908-9
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 13 October 2010; Reference: File #: 10-121172-973
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 28 December 2007; Reference: Korean Pharmacopoeia : Determination of Volume of Injection in Containers [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 2010; Reference: PFSB/ELD Notification No. 0208-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 10 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%202%28R1%29%20Guideline.pdf"> Q4B Annex 2(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__6.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-25 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-25"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 3(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Test for Particulate Contamination: Sub-Visible Particles General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in June 2008. This annex is the result of the Q4B process for Test for Particulate Contamination: Sub-Visible Particles General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2010; Reference: RDC 49/2010
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/561176/2007
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 74, No. 6, p. 909-10
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 22 October 2010; Reference: File #: 10-121191-626
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 28 December 2007; Reference: Korean Pharmacopoeia : Insoluble Particulate Matter Test for Injections [MFDS, Republic of Korea Notification ]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 2010; Reference: PFSB/ELD Notification No. 0208-2
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 11 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%203%28R1%29%20Guideline.pdf">  Q4B Annex 3(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__7.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-26 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-26"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 4A(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4 </em>in November 2008. This annex is the result of the Q4B process for Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/308671/2008
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 74, No. 66, p. 15991-2
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 13 October 2010; Reference: File #: 10-121518-692
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 27 December 2012; Reference: Korean Pharmacopoeia : Microbial Limit Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: PFSB/ELD Notification No. 0917-2
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 12 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex4A%28R1%29%20Guideline.pdf"> Q4B Annex 4A(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__8.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-27 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-27"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 4B(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-Organisms General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in November 2008. This annex is the result of the Q4B process for Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/308817/2008
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 74, No. 66, p.&nbsp;15989-90
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 18 October 2010; Reference: File #: 10-121745-378
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 27 December 2012; Reference: Korean Pharmacopoeia : Microbial Limit Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: PFSB/ELD Notification No. 0917-2
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 13 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex4B%28R1%29%20Guideline.pdf"> Q4B Annex 4B(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__9.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-28 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-28"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 4C(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4 </em>in November 2008. This annex is the result of the Q4B process for Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter. For each regulatory region this pharmacopoeial text is non-mandatory and is provided for informational purposes only. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/308867/2008
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 74, No. 66, p. 15992-3
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 20 October 2010; Reference: File #: 10-121780-106
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 27 December 2012; Reference: Korean Pharmacopoeia : Microbial Limit Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: PFSB/ELD Notification No. 0917-2
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 14 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex4C%28R1%29%20Guideline.pdf"> Q4B Annex 4C(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__10.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-29 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-29"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 5(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Disintegration Test General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in June 2009. This annex is the result of the Q4B process for Disintegration Test General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/308895/2008
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 74, No. 245, p. 68270-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 22 October 2010; Reference: File #: 10-121831-758
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 27 December 2012; Reference: Korean Pharmacopoeia : Microbial Limit Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: PFSB/ELD Notification No. 0917-3
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 15 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%205%28R1%29%20Guideline.pdf"> Q4B ANNEX 5(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__11.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-30 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-30"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 6</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Uniformity of Dosage Units General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in November 2013. This annex is the result of the Q4B process for Uniformity Dosage Units General Chapter. It contains the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">13 November 2013</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2013; Reference: CHMP/ICH/645408/2008
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2014; Reference: Vol. 79, No. 115, p. 34314-5
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 29 May 2015; Reference: File #: 15-106278-499
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 27 December 2012; Reference: Korean Pharmacopoeia : Uniformity of Dosage Units [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 April 2014; Reference: PFSB/ELD Notification No. 0417-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 13 November 2013; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 12 December 2016; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%206%20Guideline.pdf"> Q4B Annex 6 </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__12.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-31 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-31"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 7(R2)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Dissolution Test General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in October 2009. This annex is the result of the Q4B process for Dissolution Test General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada. On 11 November 2010 the ICH Steering Committee approved the second revision (R2) directly under <em>Step 4</em> without further public consultation.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">11 November 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2010; Reference: CHMP/ICH/645469/2008
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2011; Reference: Vol. 76, No. 122, p. 37129-31
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 22 October 2010; Reference: File #: 10-121855-881
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 27 December 2012; Reference: Korean Pharmacopoeia : Microbial Limit Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2011; Reference: PFSB/ELD Notification No. 0726-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 11 November 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 15 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%207%20%28R2%29%20Guideline.pdf"> Q4B Annex 7(R2) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__13.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-32 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-32"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 8(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Sterility Test General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in June 2009. This annex is the result of the Q4B process for Sterility Test General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2010; Reference: RDC 49/2010
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/645592/2008
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 74, No. 244, p. 68068-9
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 26 October 2010; Reference: File #: 10-121878-840
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 27 December 2012; Reference: Korean Pharmacopoeia : Microbial Limit Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: PFSB/ELD Notification No. 0917-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 16 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%208%28R1%29%20Guideline.pdf"> Q4B Annex 8(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__14.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-33 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-33"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 9(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Tablet Friability General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised guideline was finalised under <em>Step 4 </em>in October 2009. This annex is the result of the Q4B process for Tablet Friability General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/379801/2009
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 75, No. 64, p.&nbsp;17147
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 26 October 2010; Reference: File #: 10-121949-582
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 5 December 2014; Reference: Korean Pharmacopoeia : Microbial Limit Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2011; Reference: PFSB/ELD Notification No. 0127-2
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 17 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%209%28R1%29%20Guideline.pdf"> Q4B Annex 9(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__15.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-34 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-34"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 10(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Polyacrylamide Gel Electrophoresis General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in October 2009. This annex is the result of the Q4B process for Polyacrylamide Gel Electrophoresis General Chapter. This annex was revised (R1) on 27 September 2010 to include the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 September 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2010; Reference: RDC 49/2010
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/381133/2009
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2017; Reference: Vol. 75, No. 69, Docket No. FDA2009-D-0342,&nbsp;p. 18509
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 26 October 2010; Reference: File #: 10-122178-463
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 24 March 2017; Reference: Korean Pharmacopoeia : Polyacrylamide Gel Electrophoresis [MFDS, Republic of Korea Notification ]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2011; Reference: PFSB/ELD Notification No. 0127-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 27 September 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 10 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%2010%28R1%29%20Guideline.pdf"> Q4B Annex 10(R1) </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__1.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-35 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-35"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 11</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Capillary Electrophoresis General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4 </em>in June 2010. This annex is the result of the Q4B process for Capillary Electrophoresis General Chapter. It contains the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">9 June 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2010; Reference: RDC 49/2010
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/730028/2009
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: Vol. 75, No. 171, p. 54153-4
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 29 May 2015; Reference: File #: 15-106291-302
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 28 December 2007; Reference: Korean Pharmacopoeia : Capillary Electrophoresis [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2011; Reference: PFSB/ELD Notification No. 0127-3
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 9 June 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 10 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%2011%20Guideline.pdf"> Q4B Annex 11 </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__2.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-36 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-36"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 12</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Analytical Sieving General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in June 2010. This annex is the result of the Q4B process for Analytical Sieving General Chapter. It contains the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">9 June 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: CHMP/ICH/730808/2009
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2010; Reference: Vol. 75, No. 170, p. 53973-4
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 3 June 2015; Reference: File #: 15-106304-540
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 28 December 2007; Reference: Korean Pharmacopoeia : Particle Size Distribution Test for Preparation [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2011; Reference: PFSB/ELD Notification No. 0127-4
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 9 June 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 10 October 2011; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%2012%20Guideline.pdf"> Q4B Annex 12 </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__3.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-37 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-37"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 13</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Bulk Density and Tapped Density of Powders General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in June 2012. This annex is the result of the Q4B process for Bulk Density and Tapped Density of Powders General Chapter. It contains the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">7 June 2012</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2012; Reference: CHMP/ICH/405290/2010
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 2013; Reference: Vol. 75, No. 102, p. 31944-5
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 29 May 2015; Reference: File #: 15-106311-850
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 28 December 2007; Reference: Korean Pharmacopoeia : Determination of Bulk and Tapped Densities [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2012; Reference: PFSB/ELD Notification No. 1108-3
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 7 June 2012; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 12 December 2016; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%2013%20Guideline.pdf"> Q4B Annex 13 </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__4.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-38 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-38"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B Annex 14</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Bacterial Endotoxins Test General Chapter</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Annex was finalised under <em>Step 4</em> in October 2012. This annex is the result of the Q4B process for Bacterial Endotoxins Test General Chapter. It contains the Interchangeability Statement from Health Canada, Canada.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">18 October 2012</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2010; Reference: RDC 49/2010
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2012; Reference: CHMP/ICH/529785/2010
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 October 2013; Reference: Vol. 78, No. 205, p. 63221-2
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 29 May 2015; Reference: File #: 15-106315-995
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 27 December 2012; Reference: Korean Pharmacopoeia : Bacterial Endotoxins Test [MFDS, Republic of Korea Notification]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 March 2013; Reference: PFSB/ELD Notification No. 0321-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented; Reference: Chinese Pharmacopoeia (2020 edition) volume IV, general notes (the part of general chapters) and related general chapters, rules of developing and revision process for national pharmaceutical standards (the part of general chapters).
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 18 October 2012; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 12 December 2016; Reference: 1. Chinese Phamacopeia 2. Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B%20Annex%2014%20Guideline.pdf"> Q4B Annex 14 </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_Frequently%20Asked%20Questions_26.April__5.pdf"> Q4B Frequently Asked Questions (FAQs) </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-39 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-39"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q4B FAQs</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Frequently Asked Question</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The Q4B Expert Working Group (EWG) developed a set of Frequently Asked Questions (FAQs) to help users of the Q4B Guideline and Annexes to understand the use and implication of these documents.</p>
</p></div><!----><!----></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q4B_FAQs_FAQs.pdf">  Q4B FAQs Frequently Asked Questions (FAQs)  </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-40 ng-star-inserted"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-40"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q5A - Q5E Quality of Biotechnological Products</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-41 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-41"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q5A(R1)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in March 1997.</p>

<p>This document is concerned with testing and evaluation of the viral safety of biotechnology products derived from characterised cell lines of human or animal origin and outlines data that should be submitted in the marketing application/registration package. The purpose of this Guideline is to provide a general framework for virus testing, experiments for the assessment of viral clearance and a recommended approach for the design of viral tests and viral clearance studies.</p>

<p>Please note that a typographic error has been corrected on 23 September 1999 on Table A-1: the Genome of the Reovirus 3 is RNA (and not DNA as previously printed). The correction was integrated in the Guideline that was then renamed Q5A(R1).</p>

<p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in November 1995. This document is intended to describe the types of information that are considered valuable in assessing the structure of the expression construct used to produce recombinant DNA derived proteins.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">23 September 1999</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 4 January 2021; Reference: RDC 413/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 23 September 1999; Reference: CPMP/ICH/295/95
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 24 September 1998; Reference: Vol. 63, No. 185, p. 51074
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: These guidelines are cross-referred in M4Q and applied in the routine evaluation. See regulatory guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 January 2011; Reference: Catalogue No. E H42-2/67-18-2000E
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2010; Reference: Guidance on the Testing for Adventitious Agents of Biological Products for Human Use [Guideline-0263-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 2000; Reference: PMSB/ELD Notification No. 329
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 July 2020; Reference: NMPA, China Announcement No. 7 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 23 September 1999; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 15 November 2011; Reference: Guidelne on Biological Products Testing
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5A%28R1%29%20Guideline_0.pdf"> Q5A(R1) Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-42 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-42"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q5A(R2) EWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This topic was endorsed by the ICH Assembly in June 2019.</p>

<p>&nbsp;</p>

<p>The Q5A(R2) EWG is working on the revision of the of the Q5A(R1) Guideline, providing additional recommendations on the established and complementary approaches to control the potential viral contamination of biotechnology products: selecting and testing cell lines and other raw materials; assessing the capacity of the production process to clear infectious viruses; testing the product at appropriate steps of production.</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Dr. Joel Welch &nbsp; (FDA, United States)</p></div><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Regulatory Chair</b>: Dr. Johannes Blumel (EC, Europe)</p></div></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 2b</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">29 September 2022</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 3</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Public consultation dates:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Deadline for comments by 31 January 2023</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5A-R2_FinalConceptPaper_2019_1117.pdf"> Q5A(R2) Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5A-R2_FinalBusinessPlan_2019_1118.pdf"> Q5A(R2) Business Plan </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5A%28R2%29_EWG_WorkPlan_2022_0128.pdf"> Q5A(R2)  Work Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q5A%28R2%29_Step2_draft_Guideline_2022_0826.pdf"> Q5A(R2) Draft Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings </span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH%20Q5A%28R2%29_Step2_Presentation_2022_1005.pdf"> Q5A(R2) Step 2 Presentation </a></div><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-43 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-43"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q5B</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in November 1995. This document is intended to describe the types of information that are considered valuable in assessing the structure of the expression construct used to produce recombinant DNA derived proteins.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">30 November 1995</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 4 January 2021; Reference: RDC 413/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 1995; Reference: CPMP/ICH/139/95
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 1996; Reference: Vol. 61, p. 7006
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: These guidelines are cross-referred in M4Q and applied in the routine evaluation. See regulatory guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 January 2001; Reference: Catalogue No. H42-2/67-19-2000E
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 31 July 2019; Reference: Guidelines on the Evaluation of quality, safety and efficacy of recombinant protein products [Guideline-0317-02]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 1998; Reference: PMSB/ELD Notification No. 3
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 July 2020; Reference: NMPA, China Announcement No. 7 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 30 November 1995; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2014; Reference: Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5B%20Guideline.pdf"> Q5B Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-44 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-44"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q5C</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in November 1995. This document augments the stability Guideline (Q1A) and deals with the particular aspects of stability test procedures needed to take account of the special characteristics of products in which the active components are typically proteins and/or polypeptides.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">30 November 1995</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 4 January 2021; Reference: RDC 413/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 1995; Reference: CPMP/ICH/138/95
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 1996; Reference: Vol. 61, p. 36466
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: These guidelines are cross-referred in M4Q and applied in the routine evaluation. See regulatory guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 January 2001; Reference: Catalogue No. H42-2/67-20-2000E
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 30 November 2015; Reference: Guidelines on Stability Testing of Biological Product [Guideline-0328-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 1998; Reference: PMSB/ELD Notification No. 6
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 July 2020; Reference: NMPA, China Announcement No. 7 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 30 November 1995; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 11 December 2003; Reference: Guideline on Stability Testing of Drug Substances and Products
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TITCK, Turkey</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008;</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf"> Q5C Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-45 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-45"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q5D</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4 </em>in July 1997. This document provides broad guidance on appropriate standards for the derivation of human and animal cell lines and microbial cells used to prepare biotechnological/biological products, and for the preparation and characterisation of cell banks to be used for production.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">16 July 1997</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 4 January 2021; Reference: RDC 413/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 1997; Reference: CPMP/ICH/294/95
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 1998; Reference: Vol. 63, No. 182, p. 50244-9
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: These guidelines are cross-referred in M4Q and applied in the routine evaluation. See regulatory guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 January 2001; Reference: Catalogue No. H42-2/67-21-2000E
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2010; Reference: Guidance on the Characterization of Cell Substrates Used to Produce Biologicals [Guideline-0264-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2000; Reference: PMSB/ELD Notification No. 873
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 7 November 2021; Reference: NMPA, China Announcement No. 61 [2021]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 16 July 1997; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2014; Reference: Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5D%20Guideline.pdf"> Q5D Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-46 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-46"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q5E</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in November 2004.</p>

<p>The objective of this document is to provide principles for assessing the comparability of biotechnological/biological products before and after changes are made in the manufacturing process for the drug substance or drug product.</p>

<p>Therefore, this Guideline is intended to assist in the collection of relevant technical information which serves as evidence that the manufacturing process changes will not have an adverse impact on the quality, safety and efficacy of the drug product.</p>

<p>The document does not prescribe any particular analytical, nonclinical or clinical strategy. The main emphasis of the document is on quality aspects.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">18 November 2004</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 4 January 2021; Reference: RDC 413/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2004; Reference: CPMP/ICH/5721/03
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2005; Reference: Vol. 70, No. 125, p. 37861-2
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 15 June 2015; Reference: File #: 15-107053-353
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2009; Reference: Guidelines on comparability of biological products after change in the manufacturing process [Guideline-0316-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 April 2005; Reference: PFSB/ELD Notification No. 0426001
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 July 2020; Reference: NMPA, China Announcement No. 7 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 18 November 2004; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2014; Reference: Public Announcement for â List for ICH Guidelines Adopted.â
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TITCK, Turkey</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008;</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5E%20Guideline.pdf"> Q5E Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q5E%20Concept%20Paper.pdf"> Q5E Concept Paper </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-47 ng-star-inserted"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-47"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q6A- Q6B Specifications</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-48 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-48"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q6A</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Specifications : Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4 </em>in October 1999. This document provides guidance on the setting and justification of acceptance criteria and the selection of test procedures for new drug substances of synthetic chemical origin, and new drug products produced from them, which have not been registered previously in the ICH regions.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">6 October 1999</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 3 August 2020; Reference: RDC 359/2020 and RDC 361/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 1999; Reference: CPMP/ICH/367/96
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2000; Reference: Vol. 65, No. 251, p. 83041-63
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: These guidelines are cross-referred in M4Q and applied in the routine evaluation. See regulatory guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 29 January 2016; Reference: File #: 16-100136-12
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 23 September 2020; Reference: Specification: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances [Guideline-1053-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 2001; Reference: PMSB/ELD Notification No. 568
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 July 2020; Reference: NMPA, China Announcement No. 7 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 22 September 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 6 October 1999; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2014; Reference: Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf"> Q6A Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q6A%20Decision%20Tree.pdf"> Q6A Decision Tree </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-49 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-49"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q6B</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Specifications : Test Procedures and Acceptance Criteria for Biotechnological/Biological Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in March 1999.</p>

<p>This document provides general principles on the setting and justification of a uniform set of international specifications for proteins and polypeptides which are produced from recombinant or non-recombinant cell-culture expression systems.</p>

<p>The scope of this part is initially limited to well-characterised biotechnological products, although the concepts may be applicable to other biologicals as appropriate.</p>

<p>In view of the nature of the products, the topic of specifications include in-process controls, bulk drug, final product and stability specifications and give guidance for a Harmonised approach to determining appropriate specifications based on safety, process consistency, purity, analytical methodology, product administration and clinical data considerations.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">10 March 1999</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 1 August 2011; Reference: RDC 413/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 March 1999; Reference: CPMP/ICH/365/96
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 August 1999; Reference: Vol. 64, p. 44928
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2008; Reference: These guidelines are cross-referred in M4Q and applied in the routine evaluation. See regulatory guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 20 December 2001; Reference: File #: 01-118655-734
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 30 December 2014; Reference: Regulation on Approval and Review for Biologics, ETC. [MFDS, Republic of Korea Notification] Guidelines on the Evaluation of quality, safety and efficacy of recombinant protein products [Guideline-0324-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 2001; Reference: PMSB/ELD Notification No. 571
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 22 September 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 10 March 1999; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 3 January 2002; Reference: 1.Regulation for Registration for Biotechnological Products for Human Use
2. Guidance for "Specifications: Test Procedures and Acceptance Criteria for Biotechnological/ Biological Products"
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf"> Q6B Guideline </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-50 ng-star-inserted active"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-50"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q7 Good Manufacturing Practice</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-51 ng-star-inserted active" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-51"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q7</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4 </em>in November 2000. This document is intended to provide guidance regarding Good Manufacturing Practice (GMP) for the manufacturing of Active Pharmaceutical Ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the requirements for quality and purity that they purport or are represented to possess.</p>

<p>&nbsp;</p>

<p>This Guideline applies to the manufacture of APIs for use in human drug (medicinal) products. It applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered by this guidance, but should be performed in accordance with GMP guidelines for drug (medicinal) products as defined by local authorities.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">10 November 2000</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2014; Reference: RDC 69/14
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">COFEPRIS, Mexico</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2016; Reference: NOM-164-SSA1-2015
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2000; Reference: CPMP/ICH/4106/00
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2001; Reference: Vol. 66, No. 186, p. 49028-9
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2006; Reference: HSA, Singapore is a member of PIC/S and adopts PIC/S guidelines. Q7 is officially adopted as Part II of the PIC/S GMP guide.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 7 December 2002; Reference: Guide GUI-0104
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 16 February 2015; Reference: Regulation on Pharmaceutical Good Manufacturing Practice [MFDS, Republic of Korea Notification No.2015-35] Guidance on Good Manufacturing Practices for Active Pharmaceutical Ingredients[Guideline-0042-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2001; Reference: PMSB/ELD Notification No. 1200
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 31 December 2015; Reference: Good Manufacturing Practice(2010 Revision, Order No.79 of the Ministry of Health); Notice on Implementation of Good Manufacturing Practice(2010 Revision), No. 101 of CFDA, 2011
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 26 July 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 2001; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 May 2013; Reference: 1.Regulation for Pharmaceutical Good Manufacturing Practice 2.Public Announcement for API of Biological Products should comply with GMP
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TITCK, Turkey</span> - <span _ngcontent-c32="">Implemented; Date: 1 August 2018;</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q7%20Guideline.pdf"> Q7 Guideline  </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q7%20Concept%20paper.pdf"> Q7 Concept Paper </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-52 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-52"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q7 Q&amp;As</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Questions and Answers: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The document was finalised under <em>Step 4</em> in June 2015.</p>

<p>Experience gained with the implementation of the ICH Q7 Guideline since its finalisation in 2000 showed that uncertainties related to the interpretation of some sections exist.</p>

<p>Technical issues with regard to GMP of APIs â also in context with new ICH Guidelines - are addressed in this Questions and Answers document in order to harmonise expectations during inspections, to remove ambiguities and uncertainties, and to harmonise the inspections of both small molecules and biotech APIs.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">10 June 2015</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 11 March 2020; Reference: Perguntas &amp; Respostas: RDC 69/14 - Boas PrÃ¡ticas de FabricaÃ§Ã£o de Insumos FarmacÃªuticos Ativos
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 2016; Reference: CHMP/ICH/468930/2015
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 April 2018; Reference: Vol. 83, No. 77 p. 17556-17557
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2006; Reference: HSA, Singapore is a member of PIC/S and adopts PIC/S guidelines. Q7 is officially adopted as Part II of the PIC/S GMP guide.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 10 June 2016; Reference: File # 16-106660-852
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 5 September 2018; Reference: ICH Q7 Q&amp;A [Guideline-0888-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 March 2016; Reference: PSEHB/CND Administrative Notice
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 31 December 2015; Reference: Good Manufacturing Practice(2010 Revision, Order No.79 of the Ministry of Health); Notice on Implementation of Good Manufacturing Practice(2010 Revision), No. 101 of CFDA, 2011 annexs: computerized system validation and verification(published by CFDI, 2015)
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 23 July 2015; Reference: Swissmedic, Switzerland press release
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 May 2013; Reference: 1.Regulation for Pharmaceutical Good Manufacturing Practice 2.Public Announcement for API of Biological Products should comply with GMP
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Questions &amp; Answers </span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q7%20Q%26As%20Questions%20%26%20Answers.pdf"> Q7 Q&amp;As Questions &amp; Answers  </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q7%20Q%26As%20Concept%20Paper.pdf"> Q7 Q&amp;As Concept Paper </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q7_Q%26As_Step4_Presentation.pdf"> Q7 Q&amp;As Step 4 Presentation </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-53 ng-star-inserted active"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-53"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q8 Pharmaceutical Development</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-54 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-54"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q8(R2)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Pharmaceutical Development</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The core ICH Harmonised Guideline was finalised under <em>Step 4</em> in November 2005.</p>

<p>This Guideline is intended to provide guidance on the contents of Section 3.2.P.2 (Pharmaceutical Development) for drug products as defined in the scope of Module 3 of the Common Technical Document (ICH topic M4). The guideline does not apply to contents of submissions for drug products during the clinical research stages of drug development. However, the principles in this guideline are important to consider during these stages. This guideline might also be appropriate for other types of products. To determine the applicability of this guideline for a particular type of product, applicants should consult with the appropriate regulatory authorities.</p>

<p>The annex to the Harmonised ICH text was finalised under <em>Step 4</em> in November 2008 and incorporated into the core Guideline, which was then renamed Q8(R1). The annex provides further clarification of key concepts outlined in the core Guideline. In addition, this annex describes the principles of quality by design (QbD). The annex is not intended to establish new standards: however, it shows how concepts and tools (e.g., design space) outlined in the parent Q8 document could be put into practice by the applicant for all dosage forms. Where a company chooses to apply quality by design and quality risk management (Q9: Quality Risk Management), linked to an appropriate pharmaceutical quality system, then opportunities arise to enhance science- and risk-based regulatory approaches (see Q10: Pharmaceutical Quality System).</p>

<p>The Q8(R1) Guideline was revised in August 2009 to reflect minor corrections to Example 2 on page 23 (Q8(R2)).</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">1 August 2009</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">In the process of implementation; Date: 21 October 2024; Reference: RDC 301/19
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2009; Reference: CHMP/ICH/167068/2004
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2009; Reference: Vol. 71, No. 98
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2013; Reference: Reference made to these guidelines in Draft ASEAN Guidance for Quality By Design as an Alternative Approach to Process Validation which we adopt and publish on our website. See link to guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 11 February 2016; Reference: File #: 16-101390-659
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 28 November 2018; Reference: Quality Review Guidance for the Introduction of Quality by Design [Guideline-0214-02]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2010; Reference: PFSB/ELD Notification No. 0628-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 January 2020; Reference: NMPA, China Announcement No. 6 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 1 August 2009; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2014; Reference: Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf"> Q8(R2) Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8%28R2%29%20Concept%20Paper.pdf"> Q8(R2) Concept Paper </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations/Trainings</span><!----><!----><div _ngcontent-c33="" class="links ng-star-inserted"><!----><a _ngcontent-c33="" class="document-link ng-star-inserted" target="_blank" href="https://ich.org/page/training-programme-q8q9q10-0"> ICH Q8/Q9/Q10 Training Material </a></div></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-55 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-55"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q8/9/10 Q&amp;As (R4)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Q8/Q9/Q10 - Implementation</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>Since reaching <em>Step 4</em> and publication within the ICH regions, experiences by all parties with the implementation of the ICH Q8(R2), Q9 and Q10 Guidelines have resulted in the need for some clarification. The Questions and Answers developed by the Quality Implementation Working Group (IWG) are intended to facilitate the implementation of the Q8(R2), Q9 and Q10 Guidelines, by clarifying key issues.</p>

<p>&nbsp;</p>

<p>The document with the first set of Q&amp;As was finalised under <em>Step 4</em> in April 2009. Since then, new sets of questions were added three times, with the most recent version (Q8/Q9/Q10 Q&amp;As (R4)) approved by the Steering Committee in November 2010. The ICH Quality IWG also prepared âPoints to Considerâ covering topics relevant to the implementation of Q8(R2), Q9 and Q10, which supplement the existing Questions &amp; Answers and workshop training materials already produced by this group.</p>

<p>&nbsp;</p>

<p>The document with the first and second set of Points to Consider was finalised in June and November 2011, respectively.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">11 November 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">In the process of implementation; Date: 1 July 2022; Reference: N/A
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2010; Reference: EMA/CHMP/ICH/265145/2009
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2013;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2016; Reference: File #: 16-100246-83
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 1 March 2021; Reference: ICH Q8, Q9, Q10 Q&amp;A [Guideline-1070-02]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 29 August 2011; Reference: PFSB/ELD Administrative Notice and PFSB/CND Administrative Notice
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 January 2020; Reference: NMPA, China Announcement No. 6 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2021; Reference: Updated-Announcement for ICH Guidelines Recognition List
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Questions &amp; Answers </span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Q%26As_0.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Questions &amp; Answers  </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Points_to_Consider_2.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Points to Consider </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Concept_Paper_0.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Concept Paper </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations/Trainings</span><!----><!----><div _ngcontent-c33="" class="links ng-star-inserted"><!----><a _ngcontent-c33="" class="document-link ng-star-inserted" target="_blank" href="https://ich.org/page/training-programme-q8q9q10-0"> ICH Q8/Q9/Q10 Training Material </a></div></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-56 ng-star-inserted active"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-56"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q9 Quality Risk Management</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-57 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-57"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q9</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Quality Risk Management</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4</em> in November 2005.</p>

<p>This Guideline provides principles and examples of tools for quality risk management that can be applied to different aspects of pharmaceutical quality.</p>

<p>These aspects include development, manufacturing, distribution, and the inspection and submission/review processes throughout the lifecycle of drug substances,drug (medicinal) products, biological and biotechnological products (including the use of raw materials, solvents, excipients, packaging and labeling materials in drug (medicinal) products, biological and biotechnological products).</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">9 November 2005</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 21 August 2019; Reference: RDC 301/19 and RDC 413/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2006; Reference: CHMP/ICH/24235/2006
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 June 2006; Reference: Vol. 71, No. 106, p. 32105-6
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2013; Reference: Reference made to these guidelines in Draft ASEAN Guidance for Quality By Design as an Alternative Approach to Process Validation which we adopt and publish on our website. See link to guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2016; Reference: File #: 16-100155-230
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2008; Reference: Guideline of Quality Risk Management [Guideline-0214-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 September 2006; Reference: PFSB/ELD Notification No. 0901004
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 January 2020; Reference: NMPA, NMPA, China Announcement No. 6 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Implemented; Date: 26 July 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 9 November 2005; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2014; Reference: Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q9%20Guideline.pdf"> Q9 Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q9%20Concept%20Paper.pdf"> Q9 Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q9%20Business%20Plan.pdf"> Q9 Business Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations/Trainings</span><!----><!----><div _ngcontent-c33="" class="links ng-star-inserted"><!----><a _ngcontent-c33="" class="document-link ng-star-inserted" target="_blank" href="https://ich.org/page/q9-briefing-pack"> ICH Q9 Briefing Pack </a><a _ngcontent-c33="" class="document-link ng-star-inserted" target="_blank" href="https://ich.org/page/training-programme-q8q9q10-0"> ICH Q8/Q9/Q10 Training Material </a></div></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-58 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-58"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q9(R1) EWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Quality Risk Management</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This topic was endorsed by the ICH Assembly in November 2019.&nbsp;</p>

<p>The Q9(R1) EWG is focusing on the following harmonisation activities:</p>

<ul>
	<li>Make&nbsp;limited and specific adjustments to specific chapters and annexes of the current ICH Q9 Guideline on Quality Risk Management (QRM);</li>
	<li>Develop&nbsp;specific training materials (with examples)&nbsp;to supplement the existing ICH briefing pack on ICH Q9, as well as to explain and facilitate the implementation and application of the proposed revisions.&nbsp;</li>
</ul>

<p>Further information can be found in the Q9(R1) Concept Paper and Business Plan.</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Dr. Kevin James O'Donnell (EC, Europe)</p></div><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Regulatory Chair</b>: Mr. Alex Viehmann (FDA, United States)</p></div></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 2b</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">18 November 2021</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 3</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Public consultation dates:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Deadline for comments by 24 March 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Deadline for comments by 15 March 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Deadline for comments by 15 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Deadline for comments by 14 April 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Deadline for comments by 10 March 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Deadline for comments by 1 April 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Deadline for comments by 31 January 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Deadline for comments by 15 March 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Deadline for comments by 31 March 2022</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q9-R1_Concept%20Paper_2020_1113.pdf"> Q9(R1) Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q9-R1_BusinessPlan_2020_1026_.pdf"> Q9(R1) Business Plan </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q9%28R1%29_EWG_WorkPlan_2022_0124.pdf"> Q9(R1) Work Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q9-R1_Document_Step2_Guideline_2021_1118.pdf"> Q9(R1) Draft Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q9%28R1%29_Step_2_Presentation_2021_1126.pdf"> Q9(R1) Step 2 Presentation </a></div><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-59 ng-star-inserted active" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-59"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q8/9/10 Q&amp;As (R4)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Q8/Q9/Q10 - Implementation</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>Since reaching <em>Step 4</em> and publication within the ICH regions, experiences by all parties with the implementation of the ICH Q8(R2), Q9 and Q10 Guidelines have resulted in the need for some clarification. The Questions and Answers developed by the Quality Implementation Working Group (IWG) are intended to facilitate the implementation of the Q8(R2), Q9 and Q10 Guidelines, by clarifying key issues.</p>

<p>&nbsp;</p>

<p>The document with the first set of Q&amp;As was finalised under <em>Step 4</em> in April 2009. Since then, new sets of questions were added three times, with the most recent version (Q8/Q9/Q10 Q&amp;As (R4)) approved by the Steering Committee in November 2010. The ICH Quality IWG also prepared âPoints to Considerâ covering topics relevant to the implementation of Q8(R2), Q9 and Q10, which supplement the existing Questions &amp; Answers and workshop training materials already produced by this group.</p>

<p>&nbsp;</p>

<p>The document with the first and second set of Points to Consider was finalised in June and November 2011, respectively.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">11 November 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">In the process of implementation; Date: 1 July 2022; Reference: N/A
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2010; Reference: EMA/CHMP/ICH/265145/2009
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2013;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2016; Reference: File #: 16-100246-83
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 1 March 2021; Reference: ICH Q8, Q9, Q10 Q&amp;A [Guideline-1070-02]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 29 August 2011; Reference: PFSB/ELD Administrative Notice and PFSB/CND Administrative Notice
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 January 2020; Reference: NMPA, China Announcement No. 6 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2021; Reference: Updated-Announcement for ICH Guidelines Recognition List
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Questions &amp; Answers </span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Q%26As_0.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Questions &amp; Answers  </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Points_to_Consider_2.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Points to Consider </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Concept_Paper_0.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Concept Paper </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations/Trainings</span><!----><!----><div _ngcontent-c33="" class="links ng-star-inserted"><!----><a _ngcontent-c33="" class="document-link ng-star-inserted" target="_blank" href="https://ich.org/page/training-programme-q8q9q10-0"> ICH Q8/Q9/Q10 Training Material </a></div></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-60 ng-star-inserted active"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-60"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q10 Pharmaceutical Quality System</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-61 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-61"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q10</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Pharmaceutical Quality System</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The ICH Harmonised Guideline was finalised under <em>Step 4 </em>in June 2008.</p>

<p>This Guideline applies to the systems supporting the development and manufacture of pharmaceutical drug substances and drug products, including biotechnology and biological products, throughout the product lifecycle.</p>

<p>The elements of Q10 should be applied in a manner that is appropriate and proportionate to each of the product lifecycle stages, recognising the differences among, and the different goals of each stage.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">4 June 2008</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 21 August 2019; Reference: RDC 301/19
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2008; Reference: CHMP/ICH/214732/2007
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 April 2009; Reference: Vol. 74, No. 66, p. 15990-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2013; Reference: Reference made to these guidelines in Draft ASEAN Guidance for Quality By Design as an Alternative Approach to Process Validation which we adopt and publish on our website. See link to guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 15 February 2016; Reference: File #: 16-101419-273
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 5 September 2018; Reference: Guideline on Pharmaceutical Quality System [Guideline-0889-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 February 2010; Reference: PFSB/ ELD Notification No. 0219-1 &amp; PFSB/ NCD Notification No. 0219-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">In the process of implementation; Date: 21 January 2020; Reference: NMPA, China Announcement No. 6 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">In the process of implementation;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 4 June 2008; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2014; Reference: Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q10%20Guideline.pdf"> Q10 Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q10%20Concept%20Paper.pdf"> Q10 Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q10%20Business%20Plan.pdf"> Q10 Business Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q10_Presentation.pdf"> Q10 Presentation </a></div><!----><div _ngcontent-c33="" class="links ng-star-inserted"><!----><a _ngcontent-c33="" class="document-link ng-star-inserted" target="_blank" href="https://ich.org/page/training-programme-q8q9q10-0"> ICH Q8/Q9/Q10 Training Material </a></div></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-62 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-62"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q8/9/10 Q&amp;As (R4)</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Q8/Q9/Q10 - Implementation</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>Since reaching <em>Step 4</em> and publication within the ICH regions, experiences by all parties with the implementation of the ICH Q8(R2), Q9 and Q10 Guidelines have resulted in the need for some clarification. The Questions and Answers developed by the Quality Implementation Working Group (IWG) are intended to facilitate the implementation of the Q8(R2), Q9 and Q10 Guidelines, by clarifying key issues.</p>

<p>&nbsp;</p>

<p>The document with the first set of Q&amp;As was finalised under <em>Step 4</em> in April 2009. Since then, new sets of questions were added three times, with the most recent version (Q8/Q9/Q10 Q&amp;As (R4)) approved by the Steering Committee in November 2010. The ICH Quality IWG also prepared âPoints to Considerâ covering topics relevant to the implementation of Q8(R2), Q9 and Q10, which supplement the existing Questions &amp; Answers and workshop training materials already produced by this group.</p>

<p>&nbsp;</p>

<p>The document with the first and second set of Points to Consider was finalised in June and November 2011, respectively.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">11 November 2010</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">In the process of implementation; Date: 1 July 2022; Reference: N/A
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 December 2010; Reference: EMA/CHMP/ICH/265145/2009
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2011;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2013;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2016; Reference: File #: 16-100246-83
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 1 March 2021; Reference: ICH Q8, Q9, Q10 Q&amp;A [Guideline-1070-02]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 29 August 2011; Reference: PFSB/ELD Administrative Notice and PFSB/CND Administrative Notice
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 January 2020; Reference: NMPA, China Announcement No. 6 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2010; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 5 February 2021; Reference: Updated-Announcement for ICH Guidelines Recognition List
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Questions &amp; Answers </span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Q%26As_0.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Questions &amp; Answers  </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Other Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Points_to_Consider_2.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Points to Consider </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Document</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q8_Q9_Q10_Q%26As_R4_Concept_Paper_0.pdf"> Q8/Q9/Q10 Q&amp;As (R4) Concept Paper </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations/Trainings</span><!----><!----><div _ngcontent-c33="" class="links ng-star-inserted"><!----><a _ngcontent-c33="" class="document-link ng-star-inserted" target="_blank" href="https://ich.org/page/training-programme-q8q9q10-0"> ICH Q8/Q9/Q10 Training Material </a></div></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-63 ng-star-inserted active"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-63"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q11 Development and Manufacture of Drug Substances</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-64 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-64"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q11</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>The Guideline reached <em>Step 4</em> of the ICH process on 1 May 2012.</p>

<p>This Guideline describes approaches to developing and understanding the manufacturing process of the drug substance, and also provides guidance on what information should be provided in Module 3 of the Common Technical Document (CTD) Sections 3.2.S.2.2 â 3.2.S.2.6 (ICH M4Q). It addresses aspects of development and manufacture that pertain to drug substance, including the presence of steps designed to reduce impurities.</p>

<p>This Guideline is applicable to drug substances as defined in the Scope sections of ICH Guidelines Q6A and Q6B, but might also be appropriate for other types of products following consultation with the appropriate regulatory authorities.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">1 May 2012</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 3 August 2020; Reference: RDC 359/2020 and RDC 361/2020 and 301/2019
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 2012; Reference: CHMP/ICH/425213/2011
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 1 November 2012; Reference: Vol. 77, No. 224, p. 69634-5
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 1 January 2013; Reference: Reference made to these guidelines in Draft ASEAN Guidance for Quality By Design as an Alternative Approach to Process Validation which we adopt and publish on our website. See link to guidance.
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 12 February 2016; Reference: File #:&nbsp;16-100199-626
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 20 July 2017; Reference: Guideline of Development and Manufacture of Drug Substances [Guideline-0218-02]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 1 July 2014; Reference: PFSB/ELD Notification No. 0710-9
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">In the process of implementation; Date: 21 January 2020; Reference: NMPA, China Announcement No. 6 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 1 May 2012; Reference: ICH Guidelines apply in Switzerland automatically upon reaching Step 4: Swissmedic Journal 05/2006, p. 504
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 22 December 2014; Reference: Public Announcement for â List for ICH Guidelines Adopted.â
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11%20Guideline.pdf"> Q11 Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11%20Concept%20Paper.pdf"> Q11 Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11%20Business%20Plan.pdf"> Q11 Business Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-media ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11_Training_Material.mp4"> Q11 Training Material </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-65 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-65"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q11 Q&amp;As</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Questions &amp; Answers: Selection and Justification of Starting Materials for the Manufacture of Drug Substances</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>Since reaching <em>Step 4</em> in 2012, worldwide experience with implementation of the ICH Q11 Guideline and its recommendations on the development and manufacture of drug substances has given rise to requests for clarification relating to the selection and justification of starting materials.</p>

<p>The Q11 Implementation Working Group (IWG), established by ICH in 2014, developed a Questions and Answers (Q&amp;A) document which reached <em>Step 4</em> of the ICH Process in August 2017.</p>

<p>These Q&amp;As are intended to provide additional clarification, and to promote convergence and improve harmonisation of the considerations for the selection and justification of starting materials and on the information that should be provided in marketing authorisation applications and/or Master Files.</p>

<p>The focus of the Q&amp;A document is on chemical entity drug substances. Training materials and a training video on Q11 Q&amp;As are also available.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">23 August 2017</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Implemented; Date: 3 August 2020; Reference: RDC 359/2020 and RDC 361/2020 and 301/2019
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Implemented; Date: 1 March 2018; Reference: CHMP/ICH/809509/2016
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 26 February 2018; Reference: Vol. 83, No. 38, p. 8279-8280
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Implemented; Date: 4 January 2021;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Implemented; Date: 4 April 2018; Reference: File #: 18-103369-70
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Implemented; Date: 5 July 2018; Reference: Questions and Answers of Development and Manufacturing of Drug Substance [Guideline-0874-01]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 14 September 2018; Reference: PSEHB/PELD Administrative Notice
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Implemented; Date: 21 January 2020; Reference: NMPA, China Announcement No. 6 [2020]
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not yet implemented;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Implemented; Date: 23 August 2017;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Implemented; Date: 4 December 2017; Reference: Updated-Announcement for ICH Guidelines Recognition List
</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Questions &amp; Answers </span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11_Q%26As_Q%26As.pdf"> Q11 Q&amp;As Questions &amp; Answers </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11_Q%26As_Concept_Paper.pdf"> Q11 Q&amp;As Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11_Q%26As_Business_Plan_0.pdf"> Q11 Q&amp;As Business Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11_Q%26As_Step4_Presentation.pdf"> Q11 Q&amp;As Step 4 Presentation </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q11_TrainingDeck_Final_2018_0522.pdf"> Q11 Q&amp;As Training Material </a><a _ngcontent-c33="" class="document-media ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q11_TrainingVideo_FinalCompressed_2019_1007.mp4"> Q11 - training video (mp4) </a></div><!----><div _ngcontent-c33="" class="links ng-star-inserted"><!----><a _ngcontent-c33="" class="document-link ng-star-inserted" target="_blank" href="https://www.youtube.com/watch?v=MtwYKFjv_Mo&amp;feature=youtu.be"> Q11 - training video (youtube) </a></div></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-66 ng-star-inserted active"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-66"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q12 Lifecycle Management</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-67 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-67"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q12</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This topic was endorsed by the ICH Steering Committee in September 2014.</p>

<p>This new Guideline is proposed to provide a framework to facilitate the management of post-approval Chemistry, Manufacturing and Controls (CMC) changes in a more predictable and efficient manner across the product lifecycle.</p>

<p>Adoption of this new ICH Guideline will promote innovation and continual improvement in the biopharmaceutical sector, and strengthen quality assurance and reliable supply of product, including proactive planning of supply chain adjustments. It will allow regulators (assessors and inspectors) to better understand the firmsâ Pharmaceutical Quality Systems (PQSs) for management of post-approval CMC changes.</p>

<p>This new Guideline is intended to complement the existing ICH Q8 to Q11 Guidelines, and is composed of a core Guideline and Annexes.</p>
</p></div><!----><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 4</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">20 November 2019</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 5</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Implementation status:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">In the process of implementation; Date: 1 November 2029; Reference: N/A
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">In the process of implementation; Reference: EMA/CHMP/ICH/804273/2017,EMA/CHMP/ICH/831751/2017,EMA/CHMP/ICH/78332/2020
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Implemented; Date: 11 May 2021; Reference: Posted on FDA, United States website
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">In the process of implementation;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">In the process of implementation; Reference: File #: 20-113699-873
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">In the process of implementation; Date: 1 December 2021;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Implemented; Date: 29 October 2021; Reference: PSEHB/PED Notification No. 1029-1 &amp; PSEHB/CND Notification No. 1029-1
</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">In the process of implementation;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Not applicable;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">In the process of implementation;</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">In the process of implementation;</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline </span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf"> Q12 Guideline </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q12_Annexes_Step4_2019_1119.pdf"> Q12 Annexes </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q12%20Buisness%20Plan.pdf"> Q12 Business Plan </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q12%20Concept%20Paper.pdf"> Q12 Concept Paper </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q12EWG_Step4_IntroTrainingPresentation_2020_0206.pdf"> Q12 Step 4 Presentation </a></div><!----></article></app-file-accordion><!----></section></div></app-accordion-guidline></div></div></jaspero-accord><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-68 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-68"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q12 IWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Training on Regulatory and Technical Considerations for Pharmaceutical Product Lifecycle Management</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>Further to the Q12 Guideline reaching <em>Step 4</em> in November 2019, the Q12 IWG was established to prepare a comprehensive training programme and associated materials to facilitate an aligned interpretation and a harmonized implementation of ICH Q12 in ICH and non-ICH regions.</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Ms. Ashley Boam (FDA, United States)</p></div><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Regulatory Chair</b>: Ms. Nanna Abby Kruse (EC, Europe)</p></div></div><!----></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q12IWG_ConceptPaper_Approved_2020_0330.pdf"> Q12 IWG Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q12_IWG_WorkPlan_2022_0211.pdf"> Q12 Work Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Training Materials</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-zip ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q12_IWG_TrainingMaterial_Modules0-7_2021_0611.zip"> Q12 Training Material Modules 0-7 </a></div><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-69 ng-star-inserted active"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-69"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q13 Continuous Manufacturing of Drug Substances and Drug Products</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-70 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-70"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q13 EWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Continuous Manufacturing of Drug Substances and Drug Products</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This topic was endorsed by the Assembly in June 2018. This new Guideline is proposed to:</p>

<ul>
	<li>Capture key technical and regulatory considerations that promote harmonisation, including certain Current Good Manufacturing Practices (CGMP) elements specific to Continuous Manufacturing (CM),</li>
	<li>Allow drug manufacturers to employ flexible approaches to develop, implement, or integrate CM for the manufacture â drug substances and drug products â of small molecules and therapeutic proteins for new and existing products,</li>
	<li>Provide guidance to industry and regulatory agencies regarding regulatory expectations on the development, implementation, and assessment of CM technologies used in the manufacture of drug substances and drug products.</li>
</ul>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Dr. Sau Lee (FDA, United States)</p></div><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Regulatory Chair</b>: Dr. Yoshihiro Matsuda (MHLW/PMDA, Japan)</p></div></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 2b</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">27 July 2021</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 3</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Public consultation dates:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Deadline for comments by 7 December 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Deadline for comments by 20 December 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Deadline for comments by 13 December 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">HSA, Singapore</span> - <span _ngcontent-c32="">Deadline for comments by 30 November 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Deadline for comments by 27 December 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Deadline for comments by 30 November 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Deadline for comments by 17 December 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Deadline for comments by 31 December 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">SFDA, Saudi Arabia</span> - <span _ngcontent-c32="">Deadline for comments by 28 October 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Deadline for comments by 20 December 2021</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Deadline for comments by 30 November 2021</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q13%20Business%20Plan.pdf"> Q13 Business Plan </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q13%20Concept%20Paper.pdf"> Q13 Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q13_EWG_WorkPlan_2022_0104.pdf"> Q13 Work Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q13_Step2_DraftGuideline_%202021_0727.pdf"> Q13 Draft Guideline </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations / Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q13_Step2_Presentation_2021_1004.pdf"> Q13 Step 2 Presentation </a></div><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><section _ngcontent-c9="" class="ng-star-inserted"><app-widget-wrapper _ngcontent-c9="" _nghost-c12=""><div _ngcontent-c12="" class="widget"><!----><!----><!----><!----><!----><!----><!----><!----><app-accordion _ngcontent-c12="" _nghost-c19="" class="ng-star-inserted"><jaspero-accordion _ngcontent-c19="" class="accordion"><jaspero-accord _ngcontent-c19="" class="accordion-item ng-tns-c31-71 ng-star-inserted active"><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-71"><!----><div class="ng-star-inserted"><!----><h3 _ngcontent-c19="" class="title ng-star-inserted">Q14 Analytical Procedure Development</h3></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style=""><div class="jaspero__accord_inner_content"><!----><jaspero-accordion _ngcontent-c19="" class="subaccordion"><!----><!----><!----><!----><!----><!----><!----><jaspero-accord _ngcontent-c19="" class="sub-accordion-item ng-tns-c31-72 ng-star-inserted" style=""><div class="jaspero__accord_bar"><jaspero-variable-content class="ng-tns-c31-72"><!----><div class="ng-star-inserted"><!----><section _ngcontent-c19="" class="guidline-item-header ng-star-inserted"><span _ngcontent-c19="" class="sub-title guidline-item-header-code">Q2(R2)/Q14 EWG</span><span _ngcontent-c19="" class="sub-title guidline-item-header-title">Analytical Procedure Development and Revision of Q2 (R1) Analytical Validation</span></section></div><!----></jaspero-variable-content></div><div class="jaspero__accord_inner closed ng-trigger ng-trigger-anim" style="height: 0px;"><div class="jaspero__accord_inner_content"><!----><app-accordion-guidline _ngcontent-c19="" _nghost-c32=""><div _ngcontent-c32="" class="accordion-wrapper"><section _ngcontent-c32="" class="accordion-left"><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted" style=""><p _ngcontent-c32="" class="accordion-guideline-item-value guideline-description"><p>This topic was endorsed by the Assembly in June 2018.</p>

<p>The Q2(R2)/Q14 EWG will develop a new ICH Quality Guideline, ICH Q14, on Analytical Procedure Development, and revise the ICH Q2(R1) Guideline on Validation of Analytical Procedures, with a view to potentially combine both documents into one, for simplification and clarity.</p>

<p><strong>Q2(R1) Revision </strong></p>

<p>The scope of the revision of ICH Q2(R1) will include validation principles that cover analytical use of spectroscopic or spectrometry data (e.g., NIR, Raman, NMR or MS) some of which often require multivariate statistical analyses. The guideline will continue to provide a general framework for the principles of analytical procedure validation applicable to products mostly in the scope of Q6A and Q6B. These proposed guidelines (Q2(R2) and Q14) are intended to complement ICH Q8 to Q12 Guidelines, as well as on-going ICH Q13 for Continuous Manufacturing.</p>

<p><strong>Q14 Analytical Procedure Development Guideline </strong></p>

<p>The new guideline is proposed to harmonise the scientific approaches of Analytical Procedure Development, and to provide the principles relating to the description of Analytical Procedure Development process. This new guideline is intended to improve regulatory communication between industry and regulators and facilitate more efficient, sound scientific and risk-based approval as well as post-approval change management of analytical procedures.</p>
</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Rapporteur</b>: Dr. Yukio Hiyama (MHLW/PMDA, Japan)</p></div><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value"><b _ngcontent-c32="">Regulatory Chair</b>: Dr. David Keire (FDA, United States)</p></div></div><!----><div _ngcontent-c32="" class="accordion-guideline-item-separator ng-star-inserted" style=""><!----><div _ngcontent-c32="" class="accordion-guideline-item date ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-title">Date of <em><em class="placeholder">Step 2b</em></em>:</p><p _ngcontent-c32="" class="accordion-guideline-item-value">24 March 2022</p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item status ng-star-inserted"><p _ngcontent-c32="" class="accordion-guideline-item-value">Status: <em _ngcontent-c32="">Step 3</em></p></div><!----><div _ngcontent-c32="" class="accordion-guideline-item ng-star-inserted"><div _ngcontent-c32="" class="accordion-guideline-item-value"><!----><h3 _ngcontent-c32="" class="ng-star-inserted">Public consultation dates:</h3><!----><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">ANVISA, Brazil</span> - <span _ngcontent-c32="">Deadline for comments by 31 August 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">EC, Europe</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">FDA, United States</span> - <span _ngcontent-c32="">Deadline for comments by 28 September 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Health Canada, Canada</span> - <span _ngcontent-c32="">Deadline for comments by 13 September 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MFDS, Republic of Korea</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHLW/PMDA, Japan</span> - <span _ngcontent-c32="">Deadline for comments by 25 August 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">MHRA, UK</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">NMPA, China</span> - <span _ngcontent-c32="">Deadline for comments by 15 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">Swissmedic, Switzerland</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div><div _ngcontent-c32="" class="party-wrapper ng-star-inserted"><span _ngcontent-c32="" class="party-title">TFDA, Chinese Taipei</span> - <span _ngcontent-c32="">Deadline for comments by 31 July 2022</span></div></div></div></div></section><!----><section _ngcontent-c32="" class="accordion-right ng-star-inserted" style=""><!----><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Endorsed Documents</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2R2-Q14_EWG_Concept_Paper.pdf"> Q2(R2)/Q14 Concept Paper </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2R2-Q14_EWG_Business_Plan.pdf"> Q2(R2)/Q14 Business Plan </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2%28R2%29Q14_EWG_WorkPlan_2022_0210.pdf"> Q2(R2)/Q14 Work Plan </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">WG Presentations/Trainings</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/Q2_Q14%20ICH_Step_2_Presentation_2022_0325.pdf"> Q2(R2)/Q14 Step 2 Presentation </a></div><!----></article></app-file-accordion><app-file-accordion _ngcontent-c32="" _nghost-c33="" class="ng-star-inserted"><article _ngcontent-c33="" class="files-section"><span _ngcontent-c33="" class="files-title">Guideline</span><!----><div _ngcontent-c33="" class="files ng-star-inserted"><!----><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf"> Q2(R2) Draft Guideline </a><a _ngcontent-c33="" class="document-pdf ng-star-inserted" target="_blank" href="https://database.ich.org/sites/default/files/ICH_Q14_Document_Step2_Guideline_2022_0324.pdf"> Q14 Draft Guideline </a></div><!----></article></app-file-accordion><!----><app-experts-list _ngcontent-c32="" _nghost-c34="" class="ng-star-inserted"><div _ngcontent-c34="" class="expert-link-wrp"><a _ngcontent-c34="">WG list</a></div><ngx-smart-modal _ngcontent-c34="" customclass="expert-modal"><!----></ngx-smart-modal><!----><!----></app-experts-list></section></div></app-accordion-guidline></div></div></jaspero-accord><!----><!----></jaspero-accordion></div></div></jaspero-accord></jaspero-accordion></app-accordion><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----></div></app-widget-wrapper></section><!----><!----></section><!----><app-edit-widget _ngcontent-c9="" _nghost-c13="" class="ng-star-inserted"><!----></app-edit-widget></article></app-page><app-sidebar _ngcontent-c8="" _nghost-c10=""><!----><aside _ngcontent-c10="" class="sidebar ng-star-inserted"><!----></aside></app-sidebar></section><app-loading-spinner _ngcontent-c8="" _nghost-c11=""><!----></app-loading-spinner></app-base-page></div><app-footer _ngcontent-c0="" _nghost-c3=""><section _ngcontent-c3="" class="footer"><ul _ngcontent-c3="" class="menu"><!----><li _ngcontent-c3="" class="menu-item"><span _ngcontent-c3="">About ICH</span><ul _ngcontent-c3="" class="sub-menu"><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/mission">Mission</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/history">History</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/transparency">Transparency</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/funding">Funding</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/work-with-ich">Work with ICH</a></li><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/organisation-ich">Organisational Chart</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/members-observers">Members &amp; Observers</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/value-membership">Value of Membership</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/application-process">Application Process</a></li><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/articles-procedures">Articles &amp; Procedures</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/work-plans-reports">Work Plans &amp; Reports</a></li><!----></ul></li><li _ngcontent-c3="" class="menu-item"><span _ngcontent-c3="">Work Products</span><ul _ngcontent-c3="" class="sub-menu"><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/process-harmonisation">Process of Harmonisation</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/public-consultations">Public Consultations</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/ich-guideline-implementation">Guideline Implementation</a></li><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/ich-guidelines">All Guidelines</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/quality-guidelines">Quality Guidelines</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/safety-guidelines">Safety Guidelines</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/efficacy-guidelines">Efficacy Guidelines</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/multidisciplinary-guidelines">Multidisciplinary Guidelines</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/search-index-ich-guidelines">Index of Guidelines</a></li><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/meddra">MedDRA</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/ctd">CTD</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/electronic-standards-estri">Electronic Standards (ESTRI)</a></li><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/reflection-papers">Reflection Papers &amp; Discussion Groups</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/consideration-documents">Consideration Documents</a></li><!----></ul></li><li _ngcontent-c3="" class="menu-item"><span _ngcontent-c3="">Meetings</span><ul _ngcontent-c3="" class="sub-menu"><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/ich-calendar">ICH Calendar</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/assemblyreports">Assembly</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/management-committee-0">Management Committee</a></li><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/ich-public-events">ICH Public Events</a></li><!----></ul></li><li _ngcontent-c3="" class="menu-item"><span _ngcontent-c3="">Training</span><ul _ngcontent-c3="" class="sub-menu"><!----><!----><!----></ul></li><li _ngcontent-c3="" class="menu-item"><span _ngcontent-c3="">Newsroom</span><ul _ngcontent-c3="" class="sub-menu"><!----><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/news">News</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/publications">Publications</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/press-releases">Press Releases</a></li><!----></ul></li><!----><li _ngcontent-c3="" class="menu-item"><span _ngcontent-c3="">See also</span><ul _ngcontent-c3="" class="sub-menu"><!----><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/contact">Contact</a></li><li _ngcontent-c3="" class="sub-menu-item"><a _ngcontent-c3="" href="/page/register-be-kept-date-ich-news">Register</a></li></ul></li></ul><div _ngcontent-c3="" class="footer-bottom"><div _ngcontent-c3=""><!----><a _ngcontent-c3="" class="footer-legal-link" href="/page/legal-mentions">ICH Legal Mentions</a><a _ngcontent-c3="" class="footer-legal-link" href="/page/ich-privacy-statement">ICH Privacy Statement</a></div></div></section></app-footer></main><app-throbber _ngcontent-c0="" _nghost-c4=""><!----></app-throbber></app-root>
<script type="text/javascript" src="runtime.fe8afe99954ebc303f28.js"></script><script type="text/javascript" src="polyfills.24ecbb783423662aadca.js"></script><script type="text/javascript" src="scripts.e454dd0842cd3c67f3c5.js"></script><script type="text/javascript" src="main.deb78dc160a29bb748dc.js"></script>

</body></html>Ytext/htmlUUTF-8_+https://www.ich.org/page/quality-guidelines¯#'+/49=AEJNRVZ^bglqÔ_WebResourceResponseO è@charset "UTF-8";.slick-slider{position:relative;display:block;box-sizing:border-box;-webkit-touch-callout:none;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;touch-action:pan-y;-webkit-tap-highlight-color:transparent}.slick-list{position:relative;overflow:hidden;display:block;margin:0;padding:0}.slick-list:focus{outline:0}.slick-list.dragging{cursor:pointer;cursor:hand}.slick-slider .slick-list,.slick-slider .slick-track{-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}.slick-track{position:relative;left:0;top:0;display:block;margin-left:auto;margin-right:auto}.slick-track:after,.slick-track:before{content:"";display:table}.slick-track:after{clear:both}.slick-loading .slick-track{visibility:hidden}.slick-slide{float:left;height:100%;min-height:1px;display:none}[dir=rtl] .slick-slide{float:right}.slick-slide img{display:block}.slick-slide.slick-loading img{display:none}.slick-slide.dragging img{pointer-events:none}.slick-initialized .slick-slide{display:block}.slick-loading .slick-slide{visibility:hidden}.slick-vertical .slick-slide{display:block;height:auto;border:1px solid transparent}.slick-arrow.slick-hidden{display:none}/*!
